DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



UVB Model Validation Study

Information source: X-pert Med GmbH
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pain; Inflammation; Healthy Volunteers

Intervention: Ibuprofen, Hydrocortisone (Drug); Hydrocortisone (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: X-pert Med GmbH

Summary

Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas.

Clinical Details

Official title: Single Centre, Subject and Observer Blinded, Placebo Controlled, Cross-over Study of the Effect of Oral Ibuprofen and Topical Hydrocortisone-21-acetate on Ultraviolet Radiation (UVR) Induced Pain and Inflammation in Healthy Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome: Hyperalgesia to heat

Secondary outcome: Erythema, Skin temperature

Detailed description: Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas. Subjects that signed the informed consent and are eligible to the study will be irradiated on the back to evaluate their individual minimal erythema doses (MEDs). Read out to determine MED will be done within 24 h after UVR. A training session (without study medication) using the MED definition areas will be performed in order to introduce subjects to the testing and rating procedures. Subjects will come in within 14 days of screening to start the first Segment of the study. Eligible subjects will be randomised to receive either: 1. IB 600 mg, applied orally b. i.d., or 2. OP, applied orally b. i.d. Allocation of topical treatment to these areas will be randomly assigned to: 1. PG, 15 μl/cm2 applied topically b. i.d., or 2. HC, 15 μl/cm2 applied topically b. i.d. Defined areas will be irradiated with defined dosages of UVR. Assessment of hyperalgesia to heat and signs of inflammation (erythema, skin temperature) for all areas will be performed. Subjects return within 4 to 11 days to the study site for the second segment of the study. Treatment allocation will be crossed-over and new treatment areas will be selected on the back.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- healthy volunteers

Exclusion Criteria:

-

Locations and Contacts

X-pert Med GmbH, Graefelfing, Bavaria 82166, Germany
Additional Information

link to Sponsor and investigational site

Starting date: January 2010
Last updated: July 12, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017